Aerie Pharma (AERI) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 5, 2021 4:01 PM EDTFirst Quarter 2021 Net Revenue Per Bottle of $89, up 11.3% over Fourth Quarter 2020
First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over First Quarter 2020
Significant Progress Made Across the Pipeline
Conference Call and Webcast Today, May 5th, at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal... More
